Reading Time: < 1 minuteIn this Issue Lykos CEO Provides AdComm Feedback to FDA Commissioner Cybin Plans to Fight
Reading Time: < 1 minuteIndependent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development
Reading Time: < 1 minuteFollowing FDA’s refusal to approve Lykos Therapeutics’ MDMA-assisted therapy for PTSD New Drug Application (NDA), a key
Reading Time: 5 minutesFinal rules from DOR’s Natural Medicine Division governing Natural Medicine Businesses come in at just
Reading Time: < 1 minuteFollowing FDA’s rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD New Drug Application (NDA), the
Reading Time: 2 minutesAs I reported on Friday evening, Lykos looks set to appeal the FDA’s decision. The company said
Reading Time: 2 minutesWhile a CRL is a rejection of the NDA in its current form, it’s not
Reading Time: < 1 minuteIn this Issue Dan Crenshaw and Elon Musk Add Fuel to Lykos ‘Dumpster Fire’ Drama
Reading Time: < 1 minuteIndependent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development
Reading Time: < 1 minuteIn this Issue Sergey Brin Bets $15M on Ibogaine Startup Soneira, But Questions Loom Over